INTRODUCTION {#S1}
============

Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus that results in approximately half of the population in the United States becoming seropositive ([@R3]). In healthy individuals, cytomegalovirus (CMV) is easily resolved; however, it remains latent and can periodically reactivate, asymptomatically. CMV is superbly adept at evading components of the host's innate and adaptive immune systems; thus, maintaining suppression requires a multilayered immune response ([@R48]). This results in an interplay between viral escape mechanisms and host immune control ([@R21]). However, primary and reactivated CMV infections are both potential sources of morbidity and mortality for immunocompromised patients, in addition to being a serious congenital infection ([@R13]).

Each member of the CMV family displays species-specific tropism; therefore, animal models are required to better understand the multifaceted immune response elicited during infection. Murine CMV (MCMV) is a well-established model with similarities in genome, latency, and reactivation to HCMV ([@R59]). There are also parallels in the immune response. For example, an intact CD8^+^ T cell response correlates favorably with outcome in both humans and mice ([@R50]; [@R55]; [@R51]; [@R71]). In fact, a large fraction of the T cell compartment is devoted to CMV. In seropositive individuals, approximately 10% of circulating CD4^+^ and CD8^+^ T cells are CMV specific ([@R62]).

Compared to the well-characterized roles of classical CD8^+^ T cells during CMV infection, the immunologic contributions of non-classical CD8^+^ T cells remain poorly understood. Non-classical CD8^+^ T cells are restricted by major histocompatibility complex (MHC) class Ib molecules (e.g., human leukocyte antigen \[HLA\]-E, -F, and -G in humans), rather than MHC class Ia (i.e., HLA-A, -B, and -C in humans). These are structurally similar to MHC class Ia but are generally non-polymorphic and have lower cell surface expression ([@R60]). Some MHC class Ib molecules can also present unique types of antigens to T cells, including vitamin B metabolites, lipids, and N-formylated peptides ([@R12]).

Non-classical CD8^+^ T cells participate in the host defense against a number of bacterial and viral pathogens ([@R2]). Evidence also suggests that HLA-E-restricted CD8^+^ T cells are present following HCMV infection ([@R39]; [@R47]); however, their role during the immune response is unclear. In mice, Qa-1 (encoded by *H2-T23*) is the functional homolog of HLA-E. HLA-E and Qa-1 are normally loaded with peptides derived from the leader sequences of classical MHC molecules, referred to as Qa-1 determinant modifier (Qdm) ([@R1]; [@R5]; [@R34]). HLA-E- ([@R6]; [@R35]) and Qa-1-bound ([@R67]; [@R68]) Qdm interact with members of the CD94-NKG2 family of receptors, in addition to certain T cell receptors. Natural killer (NK) cells and CD8^+^ T cells are both repressed when HLA-E and Qa-1-Qdm engages the inhibitory receptor CD94-NKG2A ([@R69]; [@R42]). Interestingly, in an attempt to avoid the NK cell response by CD94-NKG2A engagement ([@R73]), certain HCMV strains encode their own ligand for HLA-E within the signal sequence of its glycoprotein UL40 (gpUL40) ([@R64]; [@R66]). These peptides can be identical, or nearly identical, to Qdm depending on the HCMV strain. As a result, allogenic gpUL40-reactive HLA-E-restricted CD8^+^ T cells may occur following infection with certain strains and HLA haplotypes ([@R23]).

CMV uses a variety of mechanisms to avoid the classical T cell response, including downregulation of conventional MHC class I and II molecules ([@R14]; [@R78]). Given the virus's preponderance for immune evasion, we sought to delineate the contribution of MHC class Ib-restricted CD8^+^ T cells. We demonstrate that non-classical CD8^+^ T cells are phenotypically similar to conventional CD8^+^ T cells, rather than innate-like MHC-class-Ib-restricted T cells, and capable of developing memory; this population was also sufficient to protect against MCMV-induced lethality. Using CRISPR-Cas9-generated K^b^D^b−/−^Qa-1^−/−^ mice, we determined that this population contained Qa-1-restricted T cells, which were critical for protection. In contrast to previously identified HLA-E-restricted cells, this population does not depend on Qdm or UL40-derived peptides. Together, these studies add another contributing immunologic layer against CMV. The anti-viral properties of non-classical T cells make them attractive targets not only to examine during infection, but also for vaccine development as well.

RESULTS {#S2}
=======

Non-classical CD8^+^ T Cells Participate during Acute MCMV Infection in K^b^D^b−/−^ Mice {#S3}
----------------------------------------------------------------------------------------

To study the non-classical CD8^+^ T cell response in the absence of classical CD8^+^ T cells, we took advantage of K^b^D^b−/−^ mice ([@R46]). *H-2K*^*b*^ and *H-2D*^*b*^ encode MHC class Ia molecules in mice on the C57BL/6 background; thus, any residual CD8^+^ T cells present in K^b^D^b−/−^ animals are selected by MHC class Ib molecules. As previously reported, we found greatly diminished populations of CD8^+^ T cells in naive K^b^D^b−/−^ animals ([Figure 1A](#F1){ref-type="fig"}) ([@R70]; [@R46]). However, both the frequency and absolute number of these cells robustly increased in the spleen, liver ([Figures 1A](#F1){ref-type="fig"} and [S1A](#SD1){ref-type="supplementary-material"}), and blood (data not shown) on day 7 post-MCMV infection. This response peaked by day 14 and equated to an approximate 5-fold and 17-fold expansion in the spleen and liver, respectively ([Figure 1B](#F1){ref-type="fig"}). MCMV-expanded non-classical CD8^+^ T cells subsequently began to contract by day 21 ([Figure 1B](#F1){ref-type="fig"}).

MCMV-Expanded Non-classical CD8^+^ T Cells Are Distinct from Innate-like T Cells {#S4}
--------------------------------------------------------------------------------

Many non-classical T cells have a unique innate-like phenotype and do not require clonal expansion following stimulation; this gives them access to more rapid effector functions ([@R12]). Based on the kinetics that we observed for MCMV-expanded non-classical CD8^+^ T cells, we wondered whether they were more similar to conventional T cells or maintained innate-like characteristics. The transcription factor promyelocytic leukemia zinc finger (PLZF) is thought to act as a major regulator for innate-like T cells. For example, γδ T cells ([@R30]), mucosal-associated invariant T (MAIT) cells ([@R52]), and NKT cells ([@R29]) all express PLZF. Although PLZF-expressing CD8^+^ T cells were present in naive K^b^D^b−/−^ mice, they were PLZF^neg^ and T-bet^hi^ on day 7 post-MCMV infection ([Figure S1B](#SD1){ref-type="supplementary-material"}). Non-classical T cells can also express NK1.1, such as NKT cells, or have a CD8αα homodimer instead of a CD8αβ heterodimer as their co-receptor. The liver in particular was enriched for CD8αα^+^ and NK1.1^+^ T cells in naive K^b^D^b−/−^ animals; however, neither of these populations expanded upon infection ([Figures S1C](#SD1){ref-type="supplementary-material"} and [S1D](#SD1){ref-type="supplementary-material"}). Together, these data indicate that non-classical CD8^+^ T cells are phenotypically more similar to conventional T cells than innate-like T cells, following MCMV infection.

Non-classical CD8^+^ T Cells Acquire an Effector Phenotype following Acute MCMV Infection {#S5}
-----------------------------------------------------------------------------------------

Conventional CD8^+^ T cells downregulate CD62L and upregulate CD44 expression following activation during acute infection, becoming cytotoxic T lymphocytes (CTLs) (CD44^hi^CD62L^lo^). In K^b^D^b−/−^ mice on day 7 post-MCMV infection, there was also an increase in CTLs and a reciprocal decrease in naive (CD44^Io^CD62L^hi^) CD8^+^ T cells, compared to uninfected controls ([Figures S2A](#SD1){ref-type="supplementary-material"} and [S2C](#SD1){ref-type="supplementary-material"}). However, many non-classical CD8^+^ T cells from naive K^b^D^b−/−^ animals were already CD44^hi^CD62L^lo^, potentially misconstruing interpretation ([Figures S2A](#SD1){ref-type="supplementary-material"} and [S2C](#SD1){ref-type="supplementary-material"}) ([@R31]). To better evaluate the activation status of MCMV-expanded non-classical CD8^+^ T cells, we monitored KLRG1 expression, which is upregulated on short-lived effector CD8^+^ T cells (T~EFF~, KLRG1^+^CD127). Non-classical CD8^+^ T cells do not express KLRG1 in naive animals; however, upregulation of KLRG1 began by day 5 post-infection and peaked on day 7 ([Figures 1C](#F1){ref-type="fig"}, [S2B](#SD1){ref-type="supplementary-material"}, and [S2D](#SD1){ref-type="supplementary-material"}). They also upregulated CD94-NKG2A ([Figure S2E](#SD1){ref-type="supplementary-material"}), commonly acquired in response to infection ([@R40]), and became CX3CR1^high^ ([Figures S2F](#SD1){ref-type="supplementary-material"} and [S2G](#SD1){ref-type="supplementary-material"}), which associates with terminal effector cell differentiation following MCMV challenge ([@R11]). In addition, K^b^D^b−/−^ mice did not have increased viral levels during acute infection in the spleen or liver compared to wild-type animals ([Figures S2H](#SD1){ref-type="supplementary-material"} and [S2I](#SD1){ref-type="supplementary-material"}). Following clearance in other organs, MCMV enters the salivary gland (SMG), a privileged site of infection, where there is a peak in viral replication around 14 to 21 days. In contrast to wild-type controls, K^b^D^b−/−^ animals appear to have a shift in the kinetics of MCMV replication within the SMG ([Figure S2J](#SD1){ref-type="supplementary-material"}). Altogether, these data suggest K^b^D^b−/−^ mice control MCMV in the absence of conventional CD8^+^ T cells.

The Expansion and Activation of Non-classical CD8^+^ T Cells Is MCMV Dependent {#S6}
------------------------------------------------------------------------------

Certain non-classical T cells can uniquely respond to noncognate activation through environmental cytokines, independently of T cell receptor (TCR) engagement. For example, invariant NKT (iNKT) cell activation during MCMV infection is predominantly a result of infection-induced inflammatory cytokines ([@R65]; [@R75]; [@R18]). This led us to ask whether the non-classical CD8^+^ T cell response was cytokine dependent or MCMV dependent. CD8^+^ T cells from K^b^D^b−/−^ mice were adoptively transferred into K^b^D^b−/−^.SJL recipients that were then left untreated, treated with CPG oligodeoxynucleotide (ODN) and polyinosinic-polycytidylic acid (Poly(I:C)), or infected with MCMV. CPG ODN and Poly(I:C) are TLR9 and TLR3 agonists, respectively, and were used to simulate MCMV infection, which signals through TLR3 and TLR9 ([@R63]). Donor cells in the spleen and liver of naive recipients did not undergo detectable homeostatic proliferation on day 4, and CPG ODN and Poly(I:C) treatment resulted in minimal proliferation ([Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). In contrast, a significant number of donor cells from MCMV-infected mice proliferated, particularly in the liver (p \< 0.001) compared to treated mice ([Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). In agreement with these findings, only donor cells from virally infected recipients expressed both CD69 and KLRG1 in the spleen and liver ([Figures 2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}). Altogether, these data suggest that environmental inflammation alone is insufficient for non-classical CD8^+^ T cells to proliferate and become T~EFF~ cells following MCMV infection.

The Non-classical CD8^+^T Cell Response Correlates with a Prolonged Inflammatory Phenotype following MCMV Infection {#S7}
-------------------------------------------------------------------------------------------------------------------

Having demonstrated that the non-classical CD8^+^ T cell response is dependent on viral infection, we sought to determine whether they contribute to the inflammatory cytokine profile observed during acute MCMV. Interestingly, although there was only residual interferon gamma (IFN-γ) detected in the serum of wild-type animals on day 7 post-infection, it remained elevated in K^b^D^b−/−^ mice ([Figure 3A](#F3){ref-type="fig"}). This phenotype is striking when compared to β2m^−/−^ animals at the same time-point, which lack both MHC class Ia- and Ib-restricted CD8^+^ T cells, and also had significantly less IFN-γ (p \< 0.01) ([Figure 3A](#F3){ref-type="fig"}). The high level of serum IFN-γ in K^b^D^b−/−^ mice returned to normal levels by day 14 post-infection ([Figure 3B](#F3){ref-type="fig"}). Although these differences could be due to kinetic differences or a consequence of abnormalities in β2m^−/−^ animals, non-classical CD8^+^ T cells were also capable of producing large amounts of cytokines on day 7 post-infection following restimulation *ex vivo* ([Figure 3C](#F3){ref-type="fig"}). Together, these data indicate that non-classical CD8^+^ T cells may contribute to a prolonged inflammatory milieu.

Non-classical CD8^+^ T Cells Form Memory Populations in Long-Term Infected K^b^D^b−/−^ Mice {#S8}
-------------------------------------------------------------------------------------------

We observed that K^b^D^b−/−^ animals were protected from MCMV for upward of 11 months without outward signs of illness. This coincided with elevated populations of non-classical CD8^+^ T cells in the spleen and liver of long-term infected animals compared to naive controls ([Figures S3A](#SD1){ref-type="supplementary-material"} and [S3B](#SD1){ref-type="supplementary-material"}). Given the CD44^hi^CD62L^lo^ phenotype of many naive non-classical CD8^+^ T cells, using the typical cell surface markers to distinguish central memory and effector memory populations in long-term infected animals was challenging. However, we did determine that CD44^lo^CD62L^hi^ CD8^+^ T cells were capable of becoming CD44^hi^CD62L^lo^ when transferred into congenic recipients and infected with MCMV (data not shown). We instead investigated whether non-classical CD8^+^ T cells were capable of developing a tissue-resident memory (T~RM~, CD69^+^CD103^+^) phenotype in the SMG. We found that non-classical CD8^+^ T cells were recruited to the SMG and persisted in this tissue ([Figures 4A](#F4){ref-type="fig"} and [S3C](#SD1){ref-type="supplementary-material"}). Although there were fewer total CD8^+^ T cells compared to C57BL/6 mice ([Figure 4B](#F4){ref-type="fig"}), the proportion of CD8^+^ T cells that were T~RM~ was equivalent ([Figures 4C](#F4){ref-type="fig"} and [S3D](#SD1){ref-type="supplementary-material"}).

We next wanted to determine how non-classical CD8^+^ T cells responded to secondary MCMV infection. Using an adoptive transfer approach, KLRG1CD27^+^ CD8^+^ T cells (T~M~) were isolated from long-term infected K^b^D^b−/−^ mice and 5 × 10^4^ cells were transferred into K^b^D^b−/−^.SJL recipients, which were then challenged with MCMV ([@R50]). Donor cells underwent significant expansion, comprising up to of 25% of total splenic CD8^+^ T cells, and became highly activated upon secondary challenge ([Figure 4D](#F4){ref-type="fig"}); this was greater than recipient non-classical CD8^+^ T cells, which only experienced their primary MCMV infection ([Figure 4E](#F4){ref-type="fig"}). Assuming 100% engraftment in the spleen, this accounted for roughly a four-fold increase ([Figure 4F](#F4){ref-type="fig"}). However, this is a substantial underrepresentation because donor cells were also found in other organs, including the liver and blood. In contrast, donor cells originating from naive animals constituted a very minor portion of recipient organs, and their activation was equivalent to that of recipient non-classical CD8^+^ T cells ([Figures 4G](#F4){ref-type="fig"} and [4H](#F4){ref-type="fig"}). Together these data illustrate that non-classical CD8^+^ T cells in long-term infected animals are capable of forming memory populations.

Non-classical CD8^+^ T Cells Are Sufficient to Protect against MCMV-Induced Lethality {#S9}
-------------------------------------------------------------------------------------

We next investigated the protective potential of non-classical CD8^+^ T~M~ cells against MCMV. In MCMV-infected RAG1^−/−^ mice, NK cells initially control infection, but eventually the animals succumb to the outgrowth of MCMV mutants ([@R10]). The addition of an adaptive immune component, such as CD8^+^ T~M~ cells (KLRG1CD27^+^), is able to reverse this effect; however, naive cells cannot ([@R50]). To avoid rejection of K^b^D^b^-deficient CD8^+^ T cells by NK cells in RAG1^−/−^ mice, which would be killed for their lack of these "self" molecules, we generated RAG1^−/−^K^b^D^b−/−^ animals. These mice received approximately 5 × 10^4^ CD8^+^ T~M~ cells from long-term infected K^b^D^b−/−^ mice and were subsequently infected. As expected, RAG1^−/−^K^b^D^b−/−^ controls succumbed to infection within 20 days, on average. In contrast, mice that received donor T~M~ cells were protected against MCMV-induced lethality for upward of 100 days ([Figure 4I](#F4){ref-type="fig"}). The antiviral effects of non-classical CD8^+^ T cells were confirmed by an absence of contaminating lymphocyte populations. In fact, when mice were euthanized between 10 and 16 weeks post-infection, robust populations of donor cells remained detectable ([Figure 4J](#F4){ref-type="fig"}). Taken together, these data demonstrate that non-classical CD8^+^ T cells are able to successfully control MCMV infection as the sole component of the adaptive immune system.

Loss of Qa-1 Negatively Impacts the Non-classical CD8^+^ T Cell Response during MCMV Infection {#S10}
----------------------------------------------------------------------------------------------

MCMV-expanded non-classical CD8^+^ T cells could be recognizing antigens presented by a number of MHC class Ib molecules. MHC class II-restricted CD8^+^ T cells have also been found under certain conditions, including following simian immunodeficiency virus (SIV) vaccination in rhesus macaques ([@R15]) and in HIV-infected individuals ([@R53]). We excluded MHC class II as a restricting element by comparing the expansion of non-classical CD8^+^ T cells in K^b^D^b−/−^ and β2m^−/−^ mice. Unlike K^b^D^b−/−^ animals, β2m^−/−^ mice had negligible CD8^+^ T cells present in the spleen and liver on day 7 post-infection, indicating restriction by one or more MHC class Ib molecules ([Figures 5A](#F5){ref-type="fig"} and [S4A](#SD1){ref-type="supplementary-material"}). Mice encode over 30 MHC class Ib genes, many due to gene duplications, but only 21 of these are thought to be transcribed ([@R44]). However, not all of these are capable of binding peptides, such as HFE ([@R33]) and TL (encoded by *H2-T3* and *H2-T18*) ([@R37]). Others present unique antigens that were unlikely in the context of a viral infection. For example, MR1 presents vitamin B metabolites, which are unique to bacteria and yeast ([@R28]), and M3 binds N-formylated peptides of mitochondrial or prokaryotic origin ([@R72]). We, therefore, focused on three non-classical molecules, namely, CD1d, Qa-1, and Qa-2, which have been shown to present pathogen-derived antigens ([@R9]; [@R4]; [@R61]; [@R58]).

The majority of MHC class Ib molecules are encoded in the same chromosome as MHC class Ia. CD1d is an exception, however, which allowed us to generate CD1d^−/−^K^b^D^b−/−^ mice. We found that the magnitude of the CD8^+^ T cell response to MCMV was equivalent to K^b^D^b−/−^ animals ([Figures 5B](#F5){ref-type="fig"} and [S4A](#SD1){ref-type="supplementary-material"}), indicating that CD1d was dispensable. In contrast, to test the roles of Qa-1 and Qa-2, we performed an *in vitro* restimulation assay using blocking antibodies and bone marrow-derived dendritic cells (BMDCs) derived from K^b^D^b−/−^ mice. MCMV-infected BMDCs were capable of stimulating non-classical CD8^+^ T cells from long-term infected K^b^D^b−/−^ mice to produce significantly more IFN-γ (p \< 0.001) and TNF-α (p \< 0.0001) compared to uninfected BMDCs ([Figures 5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}). Importantly although anti-Qa-2 treatment did not have any detectable effects, there was a significant decrease in TNF-α production following anti-Qa-1 treatment (p \< 0.05), and a similar trend for IFN-γ ([Figures 5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}).

To validate these data, we generated K^b^D^b−/−^Qa-1^−/−^ mice using CRISPR-Cas9 technology. Because *H2-T23* is located approximately 0.8 megabases from *H-2D*, we targeted it directly on K^b^D^b+/−^ zygotes ([Figure 6A](#F6){ref-type="fig"}). The resultant line has a 184-bp deletion in the third exon and flanking intron of *H2-T23* ([Figure 6B](#F6){ref-type="fig"}) and completely lacks Qa-1 expression at the cell surface compared to K^b^D^b−/−^Qa-1^+/+^ and K^b^D^b−/−^Qa-1^+/−^ littermate controls ([Figure 6C](#F6){ref-type="fig"}). Qa-1 is normally expressed at low levels on the cell surface and becomes upregulated following MCMV infection; this is observed in littermate control animals, however, K^b^D^b−/−^Qa-1^−/−^ mice remain Qa-1 negative ([Figures 6D](#F6){ref-type="fig"} and [6E](#F6){ref-type="fig"}). As expected, Qa-1 cell surface expression in heterozygous mice was approximately half of wild-type levels ([Figures 6C](#F6){ref-type="fig"} and [6D](#F6){ref-type="fig"}). The loss of Qa-1 in K^b^D^b−/−^ mice did not appear to affect overall T cell development in the thymus ([Figure 6F](#F6){ref-type="fig"}) or cause a further decrease in CD8^+^ T cell frequency or absolute number in naive animals ([Figures 6G](#F6){ref-type="fig"} and [6H](#F6){ref-type="fig"}). We then examined the non-classical CD8^+^ T cell response in the resultant triple knockout and littermates on day 7 post-infection. We found that K^b^D^b−/−^Qa-1^−/−^ mice had decreased frequencies of CD8^+^ T cells in the spleen, liver, and blood and decreased absolute numbers in the spleen and blood, with a similar trend in the liver ([Figures 7A](#F7){ref-type="fig"}, [7B](#F7){ref-type="fig"}, and [S4B](#SD1){ref-type="supplementary-material"}). These data implied that a large component of the non-classical CD8^+^ T cell response during acute infection was comprised of Qa-1-restricted cells. Interestingly, the CD8^+^ T cell response was also compromised in K^b^D^b−/−^Qa-1^+/−^ mice, which suggested a critical role for the level of Qa-1 expression. Remarkably, Qa-1-independent non-classical CD8^+^ T cells were also poorly activated during MCMV infection. This was evidenced by the reduced frequency of CD8^+^ T cells that were T~EFFS~ ([Figure 7C](#F7){ref-type="fig"}), terminally differentiated effectors ([Figure 7D](#F7){ref-type="fig"}), and NKG2A/C/E^+^ from K^b^D^b−/−^Qa-1^−/−^ animals ([Figure 7E](#F7){ref-type="fig"}). However, this was not a global defect because the NK cell response was unaffected by the loss of Qa-1 signaling at this time point ([Figures 7F](#F7){ref-type="fig"} and [7G](#F7){ref-type="fig"}). Long-term infected triple knockouts also had a decreased population of non-classical CD8^+^ T cells in the spleen ([Figures 7H](#F7){ref-type="fig"} and [7I](#F7){ref-type="fig"}). Given the diminished response of these cells, we sought to investigate their protective capacity by adoptively transferring CD8^+^ T~M~ (KLRG1^−^CD27^+^) cells from long-term infected K^b^D^b−/−^Qa-1^−/−^ mice into RAG1^−/−^K^b^D^b−/−^ animals. Surprisingly, in the absence of Qa-1-restricted cells, RAG1^−/−^K^b^D^b−/−^ mice had diminished survival ([Figure 7J](#F7){ref-type="fig"}). Overall, only 15% (2/13) of recipients that received CD8^+^ T~M~ from K^b^D^b−/−^Qa-1^−/−^ animals survived infection (data not shown). These data demonstrate that Qa-1-restricted T cells comprise a substantial and + essential portion of the non-classical CD8^+^ T cells responding to MCMV.

DISCUSSION {#S11}
==========

Increasing evidence demonstrates that MHC-class-Ib-restricted T cells are capable of responding to many bacterial and viral pathogens ([@R2]). Thus far, however, the non-classical T cell response to CMV has largely gone unappreciated. HLA-E-restricted T cells are detectable in a subset of HCMV seropositive individuals and respond to gpUL40 peptides *ex vivo* ([@R39]); however, their participation and protective capabilities remain ambiguous and could have allogenic and autologous potential ([@R23]). In this report, we provide evidence that non-classical CD8^+^ T cells can form memory and provide long-term protection against MCMV. We also established that the MHC class Ib molecule Qa-1 restricts a large component of this population and that both Qa-1- and non-Qa-1-restricted cells respond to MCMV with differing aptitudes.

Most non-classical T cells, such as iNKT and MAIT cells, are predisposed to rapid activation in the presence of agonist antigen and/or inflammatory cytokines but are unable to form memory ([@R12]). For example, M3-restricted T cells develop and respond before conventional CD8^+^ T cells during *Listeria monocytogenes* infection ([@R25]) but do not expand after secondary challenge ([@R25]; [@R26]). Surprisingly, we discovered that MCMV-specific non-classical CD8^+^ T cells behave similarly to conventional T~EFF~ cells, rather than innate-like T cells, during acute MCMV. This was illustrated by their lack of PLZF expression, kinetics of expansion and contraction, and formation of memory populations, including T~RM~ cells in the SMG. More importantly, we demonstrated that non-classical CD8^+^ T~M~ cells from long-term infected mice were capable of preventing lethal infection in immunocompromised mice. Others have shown that γδ T cells from previously infected animals can also prevent lethality ([@R27]; [@R57]); however, we achieved protection with up to 20 times fewer cells, akin to what was reported for conventional CD8^+^ T~M~ cells ([@R50]). This memory phenotype was somewhat surprising because non-classical T cells are believed to represent an ancient and evolutionarily conserved branch of the adaptive system ([@R22]; [@R36]). However, in agreement with our findings, a recent study reported the characterization of three Qa-1-restricted CD8^+^ T cell clones that behave similarly to conventional T cells ([@R8]).

Using neutralizing monoclonal antibodies (mAbs), we found that blocking Qa-1 inhibits the cytokine response of non-classical CD8^+^ T~M~ cells following restimulation. The essential role of Qa-1 was further established using K^b^D^b−/−^Qa-1^−/−^ mice, which exhibit an impaired CD8^+^ T cell response not only during acute infection, but also in long-term infected mice as well. It is possible this could be a consequence of increased NK cell-mediated regulation of anti-viral T cells, as recently shown with LCMV-infected Qa-1-deficient animals ([@R77]). However, we considered this unlikely because NK cells from MCMV-infected K^b^D^b−/−^Qa-1^−/−^ animals were not hyperactivated, possibly due to a lack of MHC-class-I-mediated licensing. Interestingly, the CD8^+^ T cell response was affected in both K^b^D^b−/−^Qa-1^+/−^ and K^b^D^b−/−^Qa-1^−/−^ mice, indicating that Qa-1-restricted CD8^+^ T cell selection and/or function is tightly regulated by Qa-1 expression level.

In addition to its interaction with the TCR, Qa-1 also acts as a ligand for the inhibitory receptor CD94-NKG2A on NK and CD8^+^ T cells ([@R67]; [@R68]). This inhibitory signal has been shown to restrict the magnitude of activation for virus-specific CD8^+^ T cells following poxvirus ([@R54]) and polyoma virus infection ([@R42]), as well as NK cell-mediated killing of HCMV-infected cells ([@R64]). Loss of CD94-NKG2A signaling also results in abnormal T cell activation during *Mycobacterium tuberculosis* infection ([@R4]). In several of these studies, the absence of the CD94-NKG2A inhibitory signals was presumably amplified by the absence of Qa-1-restricted regulatory CD8^+^ T cells ([@R20]). Accordingly, we predicted that the residual CD8^+^ T cells in K^b^D^b−/−^Qa-1^−/−^ mice would be hyper-responsive. Unexpectedly, the remaining CD8^+^ T cells were poorly activated after MCMV infection. Therefore, among the non-classical CD8^+^ T cell subsets, Qa-1-restricted CD8^+^ T cells may deliver the dominant response during MCMV infection. In support of this hypothesis, non-Qa-1-specific CD8^+^ T~M~ cells were less capable of protecting immunocompromised mice from MCMV-induced lethality ([Figure 7J](#F7){ref-type="fig"}). Given the critical role of Qa-1 restricted CD8^+^ T cells during MCMV infection, it will be interesting to determine whether these cells can respond to nonrelated viruses.

In addition to Qdm, Qa-1 and HLA-E present a diverse peptide repertoire. In its absence, Qa-1 preferentially binds a peptide derived from heat shock protein 60 (Hsp60), which is upregulated on stressed cells ([@R7]). Hsp60 is homologous to prokaryotic GroEL, and Qa-1 can also present GroEL-derived antigens from *Salmonella typhimurium*; however, GroEL-specific CD8^+^ T cells are cross-reactive and can lyse stressed macrophages ([@R38]). When endoplasmic reticulum amino peptidase 1 (ERAAP1) is dysfunctional, Qa-1 loads the self-peptide FL9, which allows FL9-specific CD8^+^ T cells to survey for, and eliminate, ERAAP1-deficient cells ([@R43]). In humans, HLA-E-restricted T cells specific for the HCMV gpUL40 ([@R64]; [@R66]) also lead to alloreactivity, depending on a person's HLA genotype ([@R56]). Importantly, MCMV does not encode a *UL40* homolog; therefore, the MCMV-derived antigen recognized by Qa-1-restricted CD8^+^ T cells is unlikely to induce alloreactivity. This was substantiated by MHC class Ib-restricted CD8^+^ T~M~ cells protecting against lethal infection for upward of 100 days, without apparent signs of autoimmunity. However, further work is required to identify the MCMV-derived peptide(s) presented by Qa-1.

To conclude, even though no single immune component is necessary during CMV infection, a multilayered response is compulsory to keep this highly immunoevasive virus suppressed. CMV uses multiple mechanisms to elude individual cell types, with at least seven CMV-encoded genes described to avoid the NK cell response alone ([@R76]). Here, we provide evidence of a protective MHC class Ib-restricted CD8^+^ T cell response to MCMV, including both Qa-1-restricted and non-Qa-1-restricted cells. Qa-1 and HLA-E-restricted T cells have been relatively overlooked, but recent evidence suggests that these populations have the potential to exploit immunoevasion in a CMV-based vaccine ([@R16]). Remarkably, we show here that they can form memory and substitute for conventional T cells. This suggests that Qa-1-restricted cells may represent a category of T cells positioned between innate-like and adaptive T cells, whose activity might only be revealed when the conventional T cell response is absent or impeded.

STAR⋆METHODS {#S12}
============
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### Mice {#S15}

K^b^D^b−/−^ mice were purchased from Taconic Biosciences and then maintained in-house. B6.SJL mice (Taconic) were crossed with K^b^D^b−/−^ mice to obtain congenic K^b^D^b−/−^ (K^b^D^b−/−^.SJL) animals. For certain experiments, K^b^D^b−/−^ and K^b^D^b−/−^.SJL mice were used interchangeably as K^b^D^b−/−^. CD1d^−/−^ mice (Jackson Laboratory) and RAG1^−/−^ mice (Jackson Laboratory) were crossed with K^b^D^b−/−^ mice to obtain CD1d^−/−^K^b^D^b−/−^ and RAG1^−/−^K^b^D^b−/−^ animals, respectively. C57BL/6 and β~2~m^−/−^ mice were obtained from Jackson Laboratory. C57BL^/^6 mice were used as wild-type controls. None of the experiments within these studies were blinded or randomized. Both age- and sex-matched mice were used for this study, which was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals, as defined by the National Institutes of Health (PHS Assurance \#A3284--01). Animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Brown University. All animals were housed in a centralized and AAALAC-accredited research animal facility that is fully staffed with trained husbandry, technical, and veterinary personnel.

### Generation of K^b^D^b−/−^Qa-1^−/−^ mice via CRISPR/Cas9 {#S16}

Two guideRNAs (gRNA) were used to target *H2-T23* and create a deletion in exon 3 and its flanking intron: 5′-GGCTATGT CATTCGCGGTCC-3′ (gRNA 1) and 5′-GGATTTCCCCCAAACCGCAG-3 (gRNA 2). gRNAs were selected using CHOPCHOP ([http://chopchop.cbu.uib.no](http://chopchop.cbu.uib.no/)) and CRISPR design (<http://zlab.bio/guide-design-resources>) online tools ([@R32]; [@R41]; [@R19]), and produced using the T7 gRNA SmartNuclease Synthesis Kit (System Biosciences). Cas9/gRNA injection was performed on K^b^D^b+/−^ zygotes using GeneArt CRISPR Nuclease mRNA (ThermoFischer). Founders were genotyped and bred to K^b^D^b−/−^ mice for two generations. Two sets of primers were used for genotyping K^b^D^b−/−^Qa-1^−/−^ mice. (1) Qa-1 external fwd: TCTGCTTAGGTTTGGGGTTG and Qa-1 external rev: CTACAGGGGAAAAGCAGTTTTG produce a 524 bp wild-type band and a 340 bp mutant band. (2) Qa-1 WT fwd: CATCCAAACGCCTACCCAGA and Qa-1 WT rev: TGAGGCTATGTCATTCGCGG produce a 303 bp wild-type band and no mutant PCR product.

### Virus and infection protocol {#S17}

MCMV-RVG102 was a gift from Dr. John Hamilton (Duke University) and expresses recombinant EGFP under the immediate early-1 promoter ([@R17]). Infections were performed with 5 × 10^4^ or 1 × 10^5^ PFU i.p. A mouse was only excluded from analysis if determined to be aberrantly infected, based on lack of KLRG1 upregulation in the animal. Stocks were prepared *in vivo* from SMG homogenate ([@R45]) and its titer (PFU) determined via standard plaque assay using mouse embryonic fibroblast (MEF) cells. Briefly, MEF cells were grown in 10% DMEM-serum at 37°C with 7% CO~2~ and then infected for six days in a methylcellulose overlay, fixed with 10% formalin, and stained with crystal violet to visualize plaques. Mice were considered long-term infected at \> 8 weeks post-MCMV infection.

METHOD DETAILS {#S18}
--------------

### Lymphocyte isolation {#S19}

Spleens were dissociated in 1% PBS-serum, filtered through nylon mesh, and underlayed with lympholyte-M (Cedarlane Laboratories). Alternatively, spleens were dissociated in 150 mM NH~4~Cl for 10 minutes, filtered through nylon mesh, and washed twice with 1% PBS-serum. Livers were perfused with 1% PBS-serum, dissociated using GentleMACS program E0.1 (Miltenyi Biotech) and passed through nylon mesh. Samples were washed three times in 1% PBS-serum and overlayed onto a two-step discontinuous Percoll gradient (GE Healthcare Bio-Sciences). SMG were cleaned of connective tissue and lymph nodes and dissociated in collagenase IV (Sigma-Aldrich) using GentleMACS program Heart 01.01. Samples were incubated at 37°C with shaking for 5 minutes, followed by the Heart 01.01 program; five-minute incubation and Heart 01.01 program were then repeated. Samples were filtered through nylon mesh, washed once in 1% PBS-serum, and underlayed with Lympholyte-M. All gradients were centrifuged at 2500 RPM for 20 minutes at room temperature. Blood was collected from a cardiac puncture into heparin-containing tubes. Red blood cells were lysed in 150 mM NH~4~Cl for 10 minutes and washed twice in 1% PBS-serum. To obtain serum, blood was allowed to clot at room temperature, in the absence of heparin, for 4 hours and stored at 4°C overnight. Serum was collected following centrifugation at 4°C. Live cell counts were obtained using either a hemocytometer/trypan blue exclusion or a MACSQuant/propidium iodide exclusion.

### Viral quantification by qPCR {#S20}

DNA was extracted using a DNeasy Blood and Tissue Kit (QIAGEN) and viral quantification was determined as copy number of the MCMV gene *IE1*, compared to a standard curve of the full-length *IE1* gene. For the standard, MCMV *IE1* was amplified using *IE1*-full Forward: 5′-TGTCGCCAACAAGATCCTCG-3′ and *IE1*-full Reverse: 5′-CCCTGCCTGCTGTTCTT-3′ and cloned into a pCR-Blunt vector using a Zero Blunt PCR cloning kit (Invitrogen) ([@R24]). qPCRs were performed in triplicate on a CFX384 Real-Time System (Bio-Rad) using iTaq Universal SYBR Green Supermix (Bio-Rad) and the following primers: *IE1* Forward: 5′-GAGTCTGGAACCGAAACCGT-3′ and *IE1* Reverse: 5′-GTCGCTGTTATCATTCCCCAC-3′ ([@R49]). Copy number was calculated using CFX Maestro software (Rio-Rad). Samples at, or below, the lowest standard were set to the limit of detection.

### *In vivo* cell proliferation dye experiments {#S21}

Splenocytes were labeled with cell proliferation dye eF450 (eBioscience) per the manufacturer's instructions. CD8^+^ T cells were enriched using an AutoMACS (Miltenyi Biotech) and CD8α MicroBeads (Miltenyi Biotech) and i.v. injected into K^b^D^b−/−^.SJL recipients. Two hours post-injection, recipients were left naive, stimulated with 50 mg CPG ODN (Invivogen) + 100 μg Poly(I:C) (Sigma-Aldrich), or infected with MCMV. On day 2, mice received second dose of 50 μg CPG ODN + 100 μg Poly(I:C). Donor CD8^+^ T cell proliferation was analyzed on day 4.

### Serum cytokine production {#S22}

Serum cytokines from time-course experiments were measured by LEGENDPlex bead-based immunoassay using the Mouse Th Cytokine Panel (13-plex), per the manufacturer's instructions (Biolegend). Serum IFN-γ levels on day 7 post-MCMV were determined via sandwich ELISA using the following antibodies: purified IFN-γ (clone R4--6A2, eBioscience), Biotin-IFN-γ (clone XMG1.2, eBioscience), and peroxidase-conjugated streptavidin (Jackson ImmunoResearch Labs) ([@R74]).

### Secondary MCMV challenge and survival studies {#S23}

Samples were enriched for CD8^+^ cells using an AutoMACS or OctoMACS and either CD8α MicroBeads or CD19 MicroBeads (Miltenyi Biotech). 50,000 CD8^+^ T~M~ cells (CD8^+^KLRG1^−^CD27^+^) sorted from long-term infected K^b^D^b−/−^ spleens or K^b^D^b−/−^Qa-1^−/−^ spleens were adoptively transferred per recipient. For survival studies, cells were injected i.v. into RAG1^/^K^b^D^b−/−^ mice and three hours post-injection, recipients were infected with MCMV. For secondary MCMV infections, cells were injected i.v. into K^b^D^b−/−^.SJL mice and recipients were infected two or three hours post-injection.

### *In vitro* CD8^+^ T cell stimulation and BMDC cultures {#S24}

K^b^D^b−/−^ BMDCs were prepared *in vitro* by flushing femurs and tibias with 1% PBS-serum. 1 × 10^7^ cells were grown in 10% DMEM-serum + 10 ng/ml GM-CSF (eBioscience) in a T75 flask and media was replaced on day 3. On day 6, suspended and loosely adherent cells were harvested and plated 1 × 10^5^ cells/well of a 96-well plate. BMDC were infected with 1 × 10^5^ PFU MCMV (MOI 1), plates were centrifuged at 2000 RPM for 20 minutes at room temperature, and then incubated 2 hours at 37°C. Cells were washed one time with 10% DMEM-serum and fresh 10% DMEM-serum + 10 ng/ml GM-CSF (eBioscience) was added. BMDCs were used on day 2-post infection for *in vitro* stimulation experiments. CD8^+^ T cells were enriched from individual K^b^D^b−/−^ spleens using an AutoMACS (Miltenyi Biotech) and CD8α MicroBeads (Miltenyi Biotech). 1 × 10^5^ cells were plated in triplicate onto uninfected or MCMV-infected BMDCs for 6 hours at 37°C in 10% DMEM-serum + GolgiPlug Protein Transport Inhibitor (BD Biosciences), per the manufacturer's instructions. Infected BMDCs were pretreated for at least 30 minutes with 20 μg/ml of either mouse anti-mouse Qa-1 (BD Biosciences), mouse anti-mouse Qa-2 (BioLegend), or mouse anti-mouse IgG2a isotype control (eBioscience). Antibodies were also present throughout the 6-hour incubation. Following incubation, triplicate samples were pooled and stained for intracellular IFN-γ and TNF-α production. For restimulation of cells on day 7 post-infection, wells of a 96-well plate were coated with 0.5 μg anti-mouse CD3 and CD28 antibodies (eBioscience).

### Antibodies and flow cytometry {#S25}

Cells were stained in 1% PBS-serum containing Fc block (2.4G2) and cell surface antibodies for 20 minutes on ice in the dark. Qa-1 staining was performed with a Biotin-conjugated Qa-1 antibody for 30 minutes on ice, followed by a Streptavidin-conjugated fluorophore for 30 minutes. Staining with CD1d tetramer (NIH Tetramer Core Facility) was performed for 15 minutes at room temperature and 15 minutes on ice. For intracellular staining, cells were fixed using Cytofix/Cytoperm (BD Biosciences) for 30 minutes and stained in Perm/Wash Buffer (BD Biosciences) for 30 minutes. For intranuclear staining, cells were fixed using Fixation/Permeabilization Solution (eBioscience) for 30 minutes and stained in Permeabilization Buffer (eBioscience) for 30 minutes. Samples were run on a FACSAria III (BD Biosciences) or MACSQuant (Miltenyi Biotech) and analyzed using FlowJo (Tree Star Inc.). The mAbs listed below were used for flow cytometry and purchased from BioLegend, eBioscience, Thermo Fischer Scientific, or BD Biosciences: APC-CD45.2, APC-CD103, APC-CX3CR1, APC-Streptavidin, APC-eF780-CD44, APC-eF780-CD45.1, APC-eF780-CD45.2, APC-eF780-KLRG1, Biotin-Qa-1, BV421-CD127, BV421-CD1d loaded tetramer, BV510-TCRβ, BV570-CD4, BV605-CD8a, BV711-CD62L, BV785-NK1.1, eF450-CD8a, eF450-CD45.1, eF450-TNF-α, FITC-CD69, FITC-Granzyme B, FITC-NKG2A/C/E, FITC-TCRβ, PE-CD8β.2, PE-CD19, PE-CD27, PE-CD69, PE-CX3CR1, PE-IFN-γ, PE-PLZF, PE-TCRβ, PE-Cy7-Granzyme B,PE-Cy7-IFN-γ, PE-Cy7-KLRG1, PE-Cy7-T-bet, PerCP-Cy5.5-CD69, PerCP-Cy5.5-TCRβ, PerCP-eF710-CD27, PerCP-eF710-CD127, PerCP-eF710-NKG2A/C/E. Brilliant Stain Buffer (BD Biosciences) was added to staining cocktail when Brilliant Violet antibodies were used.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S26}
---------------------------------------

### Statistical analysis {#S27}

All analyses for determining statistical significance were performed using Prism 7.0 (Graph-Pad Software, Inc.). Unpaired two-tailed Student's t tests were used to compare two individual groups and Log-rank (Mantel Cox) tests were used for survival studies. Graphs represent the mean and error bars indicate standard error of the mean (SEM). The number of animals/sample size and total experimental replicates are indicated within each figure legend. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 and \*\*\*\*p \< 0.0001.
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![Non-classical CD8^+^ T Cells Participate during Acute MCMV Infection in K^b^D^b−/−^ Mice\
(A) Representative staining of CD8^+^ T cells in the spleen and liver of K^b^D^b−/−^ mice on day 0 and day 7 post-MCMV infection.\
(B) Frequency (black) and number (gray) of CD8^+^ T cells in the spleen and liver of K^b^D^b−/−^ mice on indicated days post-MCMV infection (n = 9). Numbers indicate fold change of cell number compared to day zero.\
(C) Frequency of CD8^+^ T~EFF~ cells (KLRG1^+^CD127^−^) in the spleen (---) and liver (- -) of K^b^D^b−/−^ mice on indicated days post-MCMV infection (n = 9). Data are pooled from three independent experiments and represent mean ± SEM.\
See also [Figures S1](#SD1){ref-type="supplementary-material"} and [S2](#SD1){ref-type="supplementary-material"}.](nihms-1526697-f0002){#F1}

![The Expansion and Activation of Non-classical CD8^+^ T Cells is MCMV Dependent\
(A) Representative cell proliferation dye (CPD) labeling of donor non-classical CD8^+^ T cells (CD45.2^+^) in the spleen and liver of K^b^D^b−/−^.SJL (CD45.1^+^) recipients on day 4 post-transfer. Recipients were left naive (black), treated with Poly(I:C) + CpG (gray), or infected with MCMV (blue). Histograms are gated on total donor non-classical CD8^+^ T cells.\
(B--D) Frequencies of donor CD8^+^ T cells that (B) have undergone more than one cycle of proliferation, (C) are CD69^+^, or (D) are KLRG1^+^ (n = 5--6).\
Data are pooled from two independent experiments and represent mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001.](nihms-1526697-f0003){#F2}

![The Non-classical CD8^+^ T Cell Response Correlates with a Prolonged Inflammatory Phenotype following MCMV Infection\
(A) Serum IFN-γ levels from C57BL/6, K^b^D^b−/−^ and β~2~m^−/−^ mice on day 7 post-MCMV infection were determined by sandwich ELISA (n = 7).\
(B) Serum IFN-γ levels from K^b^D^b−/−^ mice on indicated days post-MCMV infection were determined by bead-based immunoassay (n = 8--9). Dotted line indicates limit of detection.\
(C) Frequency of non-classical CD8^+^ T cells positive for indicated cytokine after restimulation *ex vivo* with CD3 and CD28 or media on day 7 post-MCMV infection (n = 13).\
Data are pooled from two (A and C) or three (B) independent experiments and represent mean ± SEM. \*p \< 0.05, ^\*\*^p \< 0.01, ^\*\*\*^p \< 0.001, and ^\*\*\*\*^p \< 0.0001.](nihms-1526697-f0004){#F3}

![Non-classical CD8^+^ T Cells Form Memory Populations and Are Sufficient to Protect against MCMV-Induced Lethality\
(A and B) Frequency (A) and number (B) of non-classical CD8^+^ T cells in the SMG from long-term infected K^b^D^b−/−^ and C57BL/6 mice (n = 12).\
(C) Frequency of CD8^+^ T~RM~ cells (CD103^+^CD69^+^) in the SMG from long-term infected K^b^D^b−/−^ and C57BL/6 mice (n = 12).\
(D) Representative expansion and activation of donor non-classical CD8^+^ T cells (CD45.2^+^) transferred into K^b^D^b−/−^.SJL (CD45.1^+^) recipients, on day 7 post-MCMV infection. Donor CD8^+^ T~M~ (KLRG1^−^CD27^+^) cells were sorted from long-term infected K^b^D^b−/−^ mice.\
(E) Frequency of donor and recipient non-classical CD8^+^ T~EFF~ cells (KLRG1^+^CD127^−^) on day 7 post-infection (n = 7).\
(F) Fold change of donor CD8^+^ T cell number, assuming 100% engraftment in indicated organ on day 7 post-infection (n = 7).\
(G) Frequency of donor and recipient non-classical CD8^+^ T~EFF~ cells (KLRG1^+^CD127) on day 7 post-infection (n = 8); KLRG1CD27^+^ donor cells were sorted from naive K^b^D^b−/−^ mice prior to infection.\
(H) Fold change of donor CD8^+^ T cell number, assuming 100% engraftment in indicated organ, on day 7 post-infection (n = 8).\
(I) Survival of RAG1^−/−^K^b^D^b−/−^ mice with (---) or without (- -) adoptive transfer of 5 × 10^4^ sorted CD8^+^ T~M~ cells (KLRG1CD27^+^) from long-term infected K^b^D^b−/−^ mice (n = 6). Statistical analysis determined by Mantel-Cox test.\
(J) Fold-change of donor cells in the spleen (n = 12) and liver (n = 6) of RAG1^−/−^K^b^D^b−/−^ recipients upon euthanization between 10 to 16 weeks post-infection.\
Data represent mean ± SEM and are pooled (A--C, E--H, and I) or representative (D and I) of at least two independent experiments. \*\*p \< 0.01, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001.\
See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms-1526697-f0005){#F4}

![β~2~m and Qa-1 Contribute in the Non-classical CD8^+^ T Cell Response following MCMV Infection\
(A and B) Frequency of non-classical CD8^+^ T cells in the spleen and liver of (A) K^b^D^b−/−^ and β~2~m^−/−^ mice on day 7 post-MCMV infection (n = 6--12) or (B) K^b^D^b−/−^ and CD1d^−/−^K^b^D^b−/−^ mice (n = 7--9).\
(C and D) Frequency of (C) IFN-γ^+^ and (D) TNF-α^+^ non-classical CD8^+^ T cells during *ex vivo* stimulation with uninfected or MCMV-infected K^b^D^b−/−^ BMDCs in the presence of anti-Qa-1, anti-Qa-2, or immunoglobulin G (IgG) isotype control antibodies. CD8^+^ T cells were enriched from long-term infected K^b^D^b−/−^ mice (n = 16).\
Data are pooled from at least two independent experiments and represent mean ± SEM. \*p \< 0.05, ^\*\*\*^p \< 0.001, and ^\*\*\*\*^p \< 0.0001.\
See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1526697-f0006){#F5}

![Non-classical CD8^+^ T Cells Are Unaffected by the Loss of Qa-1 Signaling in Naive K^b^D^b−/−^Qa-1^−/−^ Mice\
(A) K^b^D^b−/−^Qa1^−/−^ mice were generated using two guideRNA (gRNA; blue) targeted to exon 3 of *H2-T23* and its flanking intron in K^b^D^b+/−^ zygotes. Protospacer adjacent motifs (PAM; green) and beginning and end of deleted region (arrows) are indicated.\
(B) Sequence of wild-type and mutant *H2-T23*, including premature stop codon (\*).\
(C and D) Qa-1 MFI on (C) total naive thymocytes (n = 3--4) and (D) splenic CD19^+^ lymphocytes on day 7 post-MCMV infection (n = 3--4) compared to secondary control (dotted line) from K^b^D^b−/−^Qa-1^+/+^ (WT), K^b^D^b−/−^Qa-1^+/−^ (HET), and K^b^D^b−/−^Qa-1^−/−^ (KO) mice.\
(E) Representative histograms of Qa-1 expression on CD19^+^ lymphocytes from the spleen of indicated mice.\
(F) The CD4^−^CD8^−^ double negative (DN), CD4^+^CD8^+^ double positive (DP), and CD4^+^ and CD8^+^ single positive (SP) stages of T cell development in the thymus of indicated mice (n = 6--8).\
(G) Frequency and (H) absolute number of CD8^+^ T cells in indicated organs from naive animals (n = 6--8).\
Data represent mean ± SEM and are pooled from two (F--H) or representative of two (C--E) independent experiments. \*p \< 0.05, ^\*\*^p \< 0.01, ^\*\*\*^p \< 0.001, and ^\*\*\*\*^p \< 0.0001.](nihms-1526697-f0007){#F6}

![Loss of Qa-1 Negatively Impacts the Non-classical CD8^+^ T Cell Response and Their Protective Capabilities\
(A and B) Frequency (A) and absolute number (B) of non-classical CD8^+^ T cells in the spleen, liver, and blood of K^b^D^b−/−^Qa-1^+/+^, K^b^D^b−/−^Qa-1^+/−^, and K^b^D^b−/−^Qa-1^−/−^ mice on day 7 post-MCMV infection (n = 9--11).\
(C--G) KLRG1^+^CD127^−^ (C), KLRG1^+^CX3CR1^+^ (D), and NKG2A/C/E^+^ (E) non-classical CD8^+^ T cells and KLRG1^+^ (F) and NKG2A/C/E^+^ NK (G) cells on day 7 post-MCMV infection from indicated organs of K^b^D^b−/−^Qa1^+/+^, K^b^D^b−/−^Qa1^+/−^, and K^b^D^b−/−^Qa1^−/−^ mice (n = 9--11).\
(H and I) Frequency (H) and absolute number (I) of CD8^+^ T cells from the spleen and liver of long-term infected K^b^D^b−/−^Qa1^+/+^ (DKO) and K^b^D^b−/−^Qa1^−/−^ (TKO) mice (n = 5--7).\
(J) Survival of RAG1^−/−^K^b^D^b−/−^ mice with (---, n = 5) or without (- -, n = 6) adoptive transfer of 5 × 10^4^ sorted CD8^+^ T~M~ cells (KLRG1CD27^+^) from long-term infected K^b^D^b−/−^Qa-1^−/−^ mice. Statistical analysis determined by Mantel-Cox test.\
Data are pooled from two (H and I) or three independent experiments (A--G) or representative of three independent experiments (J). Data represent mean ± SEM. \*p \< 0.05, ^\*\*^p \< 0.01, ^\*\*\*^p \< 0.001, and ^\*\*\*\*^p \< 0.0001.\
See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1526697-f0008){#F7}

  ------------------------------------------------------------- ------------------------------- ------------------------------------------
  REAGENT or RESOURCE                                           SOURCE                          IDENTIFIER

  Antibodies                                                                                    

  APC anti-mouse CD45.2                                         Thermo Fischer Scientific       Cat\#: 17--0454-82; RRID: AB_469400

  APC anti-mouse CD103                                          Thermo Fischer Scientific       Cat\#: 17--1031-80; RRID: AB_1106993

  APC anti-mouse CX3CR1                                         BioLegend                       Cat\#: 149007; RRID: AB_2564491

  APC Streptavidin                                              Thermo Fischer Scientific       Cat\#: 17--4317-82

  APC-eF780 anti-human/mouse CD44                               Thermo Fischer Scientific       Cat\#: 47--0441-82; RRID: AB_1272244

  APC-eF780 anti-mouse CD45.1                                   Thermo Fischer Scientific       Cat\#: 47--0453-82; RRID: AB_1582228

  APC-eF780 anti-mouse CD45.2                                   Thermo Fischer Scientific       Cat\#: 47--0454-82; RRID: AB_1272175

  APC-Cy7 anti-mouse/human KLRG1                                BioLegend                       Cat\#: 138426; RRID: AB_2566554

  Biotin anti-mouse IFN-γ                                       Thermo Fischer Scientific       Cat\#: 13--7311-85; RRID: AB_466937

  Biotin anti-mouse Qa-1                                        BD Biosciences                  Cat\#: 559829; RRID: AB_397345

  BV421 anti-mouse CD127                                        BioLegend                       Cat\#: 135027; RRID: AB_2563103

  BV421 mouse CD1d tetramer loaded with PBS-57                  NIH Tetramer Core Facility      N/A

  BV510 anti-mouse TCRβ                                         BioLegend                       Cat\#: 109234; RRID: AB_2562350

  BV570 anti-mouse CD4                                          BioLegend                       Cat\#: 100542; RRID: AB_2563051

  BV605 anti-mouse CD8a                                         BioLegend                       Cat\#: 100744; RRID: AB_2562609

  BV711 anti-mouse CD62L                                        BioLegend                       Cat\#: 104445; RRID: AB_2564215

  BV785 anti-mouse NK1.1                                        BioLegend                       Cat\#: 108749; RRID: AB_2564304

  eF450 anti-mouse CD8a                                         Thermo Fischer Scientific       Cat\#: 48--0081-82; RRID: AB_1272198

  eF450 anti-mouse CD45.1                                       Thermo Fischer Scientific       Cat\#: 48--0453-80; RRID: AB_1272225

  eF450 anti-mouse TNF-α                                        Thermo Fischer Scientific       Cat\#: 48--7321-80; RRID: AB_1548828

  FITC anti-mouse CD69                                          Thermo Fischer Scientific       Cat\#: 11--0691-85; RRID: AB_465120

  FITC anti-mouse Granzyme B                                    Thermo Fischer Scientific       Cat\#: 11--8898-82; RRID: AB_10733414

  FITC anti-mouse NKG2A/C/E                                     BD Biosciences                  Cat\#: 550520; RRID: AB_393723

  FITC anti-mouse TCRβ                                          BioLegend                       Cat\#: 109206; RRID: AB_313429

  FITC anti-mouse TCRβ                                          Thermo Fischer Scientific       Cat\#: 11--5961-82; RRID: AB_465323

  PE anti-mouse CD8β.2                                          BD Biosciences                  Cat\#: 553041; RRID: AB_394577

  PE anti-mouse CD19                                            Thermo Fischer Scientific       Cat\#: 12--0193-82; RRID: AB_657659

  PE anti-mouse/human/rat CD27                                  Thermo Fischer Scientific       Cat\#: 12--0271-82; RRID: AB_465614

  PE anti-mouse CD69                                            Thermo Fischer Scientific       Cat\#: 12--0691-83; RRID: AB_465733

  PE anti-mouse CX3CR1                                          BioLegend                       Cat\#: 149005; RRID: AB_2564314

  PE anti-mouse IFN-γ                                           Thermo Fischer Scientific       Cat\#: 12--7311-82; RRID: AB_466193

  PE anti-mouse PLZF                                            BioLegend                       Cat\#: 145804; RRID: AB_2561973

  PE anti-mouse TCRβ                                            Thermo Fischer Scientific       Cat\#: 12--5961-83; RRID: AB_466067

  PE-Cy7 anti-mouse Granzyme B                                  Thermo Fischer Scientific       Cat\#: 25--8898-80; RRID: AB_10853338

  PE-Cy7 anti-mouse IFN-γ                                       Thermo Fischer Scientific       Cat\#: 25--7311-82; RRID: AB_469680

  PE-Cy7 anti-mouse KLRG1                                       Thermo Fischer Scientific       Cat\#: 25--5893-82; RRID: AB_1518768

  PE-Cy7 anti-human/mouse T-bet                                 Thermo Fischer Scientific       Cat\#: 25--5825-80; RRID: AB_11041809

  PerCP-Cy5.5 anti-mouse CD69                                   BD Biosciences                  Cat\#: 561931; RRID: AB_10892815

  PerCP-Cy5.5 anti-mouse TCRβ                                   BioLegend                       Cat\#: 109228; RRID: AB_1575173

  PerCP-eF710 anti-mouse/rat/human CD27                         Thermo Fischer Scientific       Cat\#: 46--0271-80; RRID: AB_1834448

  PerCP-eF710 anti-mouse CD127                                  Thermo Fischer Scientific       Cat\#: 46--1273-80; RRID: AB_2573709

  PerCP-eF710 anti-mouse NKG2A/C/E                              Thermo Fischer Scientific       Cat\#: 46--5896-82; RRID: AB_10853352

  Peroxidase-conjugated Streptavidin                            Jackson ImmunoResearch          Cat\#: 016--030-084; RRID: AB_2337238

  Purified anti-mouse CD3e                                      Thermo Fischer Scientific       Cat\#: 14--0031-85; RRID: AB_467050

  Purified anti-mouse CD16/CD32 (Fc block, 2.4G2)               In-house produced               N/A

  Purified anti-mouse CD28                                      Thermo Fischer Scientific       Cat\#: 14--0281-85; RRID: AB_467191

  Purified anti-mouse IFN-γ                                     Thermo Fischer Scientific       Cat\#: 14--7312-85; RRID: AB_468470

  Purified anti-mouse IgG2a kappa Isotype Control               Thermo Fischer Scientific       Cat\#: 16--4724-85; RRID: AB_470165

  Purified anti-mouse Qa-1b                                     BD Biosciences                  Cat\#: 559827; RRID: AB_397344

  Purified anti-mouse Qa-2                                      BioLegend                       Cat\#: 121711; RRID: AB_2650759

  Virus Strains                                                                                 

  MCMV-RVG102                                                   Produced in house               [@R17]

  Chemicals, Peptides, and Recombinant Proteins                                                 

  Ammonium chloride                                             Fisher Scientific               Cat\# A661--500

  Brilliant Stain Buffer                                        BD Biosciences                  Cat\#: 563794

  CPG ODN 1826                                                  InvivoGen                       Cat\#: tlrl-modn

  Collagenase, Type IV                                          Sigma-Aldrich                   Cat\#: C5138

  Fixation and Permeabilization Solution                        BD Biosciences                  Cat\#: 554722

  Fixation/Permeabilization Concentrate                         eBioscience                     Cat\#: 00--5123-43

  Fixation/Permeabilization Diluent                             eBioscience                     Cat\#: 00--5223-56

  GolgiPlug Protein Transport Inhibitor (Brefeldin A)           BD Biosciences                  Cat\#: 555029

  Heparin sodium salt                                           Sigma-Aldrich                   Cat\#: H3393--500KU

  Lympholyte-M                                                  Cedarlane Laboratories          Cat\#: CL5035

  Percoll                                                       GE Healthcare                   Cat\#: 17--0891-01

  Permeabilization Buffer (10X)                                 eBioscience                     Cat\#: 00--8333-56

  Perm/Wash Buffer                                              BD Biosciences                  Cat\#: 554723

  Peroxidase Substrate Solution A                               KPL                             Cat\#: 50--64-02

  Peroxidase Substrate Solution B                               KPL                             Cat\#: 50--65-02

  Polyinosinic--polycytidylic acid potassium salt (Poly(I:C))   Sigma-Aldrich                   Cat\#: P9582--50MG

  Recombinant Murine GM-CSF Protein                             eBioscience                     Cat\#: 14--8331

  UltraComp eBeads, Compensation Beads                          Invitrogen                      Cat\#: 01--2222-42

  Critical Commercial Assays                                                                    

  CD8a (Ly-2) Microbeads, Mouse                                 Miltenyi Biotec                 Cat\#: 130--049-401

  CD8a (Ly-2) Microbeads, Mouse                                 Miltenyi Biotec                 Cat\#: 130--117-044

  CD19 Microbeads, Mouse                                        Miltenyi Biotec                 Cat\#: 130--052-201

  Cell Proliferation Dye, eF450                                 eBioscience                     Cat\#: 65--0842-85

  DNeasy Blood and Tissue Kit                                   QIAGEN                          Cat\#: 69506

  GeneArt CRISPR Nuclease mRNA                                  ThermoFischer                   Cat\#: A29378

  iTaq Universal SYBR Green Supermix                            Bio-Rad                         Cat\#: 1725121

  LEGENDPlex Mouse Th Cytokine Panel (13-plex)                  BioLegend                       Cat \#: 740005

  T7 gRNA SmartNuclease Synthesis Kit                           System Biosciences              Cat\#: CAS510A-KIT

  Zero Blunt PCR Cloning Kit                                    Invitrogen                      Cat\#: 44--0302

  Experimental Models: Mouse Strains                                                            

  β~2~m^−/−^                                                    Jackson                         Cat \#: 002087; RRID: IMSR_JAX:002087

  B6.SJL                                                        Taconic                         Cat \#: 4007; RRID: IMSR_TAC:4007

  C57BL/6 (B6)                                                  Jackson                         Cat \#: 000664; RRID: IMSR_JAX:000664

  CD1d^−/−^                                                     Jackson                         Cat \#: 008881; RRID: IMSR_JAX:008881

  CD1d^−/−^K^b^D^b−/−^                                          This paper                      N/A

  KbDb^−/−^                                                     Taconic                         Cat \#: 4215

  KbDb^−/−^.SJL                                                 This paper                      N/A

  K^b^D^b−/−^Qa-1^−/−^                                          This paper                      N/A

  RAG1^−/−^                                                     Jackson                         Cat \#: 002216; RRID: IMSR_JAX:002216

  RAG1^−/−^K^b^D^b−/−^                                          This paper                      N/A

  Oligonucleotides                                                                              

  *H2-T23* gRNA1: 5′-GGCTATGTCATTCGCGGTCC-3′                    Produced in house               N/A

  *H2-T23* gRNA2: 5′-GGATTTCCCCCAAACCGCAG-3                     Produced in house               N/A

  Qa-1 external fwd: 5′-TCTGCTTAGGTTTGGGGTTG-3′                 IDT                             Custom

  Qa-1 external rev: 5′-CTACAGGGGAAAAGCAGTTTTG-3′               IDT                             Custom

  Qa-1 WT fwd: 5′-CATCCAAACGCCTACCCAGA-3′                       IDT                             Custom

  Qa-1 WT rev: 5′-TGAGGCTATGTCATTCGCGG-3′                       IDT                             Custom

  *IE1* Forward: 5′-GAGTCTGGAACCGAAACCGT-3′                     IDT                             [@R49]

  *IE1* Reverse: 5′-GTCGCTGTTATCATTCCCCAC-3′                    IDT                             [@R49]

  *IE1*-full Forward: 5′-TGTCGCCAACAAGATCCTCG-3′                IDT                             [@R24]

  *IE1*-full Reverse: 5′-CCCTGCCTGCTGTTCTT-3′                   IDT                             [@R24]

  Software and Algorithms                                                                       

  CFX Maestro                                                   Bio-Rad                         N/A

  CHOPCHOP, v1                                                  [@R32];\                        <http://chopchop.cbu.uib.no>
                                                                [@R41]                          

  CRISPR Design, v1                                             [@R19]                          <http://zlab.bio/guide-design-resources>

  FlowJo, v10                                                   FlowJo, LLC (Tree Star, Inc.)   <https://www.flowjo.com>

  Prism 7.0                                                     GraphPad Software               <https://www.graphpad.com>

  Other                                                                                         

  autoMACS                                                      Miltenyi Biotec                 N/A

  BD FACSAria III                                               BD Biosciences                  N/A

  CFX384 Real-Time System                                       Bio-Rad                         N/A

  gentleMACS                                                    Miltenyi Biotec                 N/A

  MACSQuant                                                     Miltenyi Biotec                 N/A

  OctoMACS                                                      Miltenyi Biotec                 N/A
  ------------------------------------------------------------- ------------------------------- ------------------------------------------

###### Highlights

-   MHC class Ib-restricted CD8^+^ T cells participate during MCMV infection

-   This population behaves like conventional T cells, rather than innate-like T cells

-   These cells can protect against MCMV-induced lethality without other T and B cells

-   Qa-1-restricted cells are an essential component for the non-classical response
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